TGen, Genomic Health ID Potential Oxaliplatin Response Genes; Findings May Enhance Colon Cancer Test

The study identified 27 genes that might impact colon cancer patients' response to oxaliplatin, a finding that could help Genomic Health add a treatment benefit indication to its Oncotype DX test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.